Last reviewed · How we verify

Maxitrol® — Competitive Intelligence Brief

Maxitrol® (Maxitrol®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical ophthalmic corticosteroid-antibiotic combination. Area: Ophthalmology.

marketed Topical ophthalmic corticosteroid-antibiotic combination Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Maxitrol® (Maxitrol®) — St. Jude Children's Research Hospital. Maxitrol is a topical ophthalmic combination that reduces inflammation and bacterial infection in the eye through corticosteroid and antibiotic action.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Maxitrol® TARGET Maxitrol® St. Jude Children's Research Hospital marketed Topical ophthalmic corticosteroid-antibiotic combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical ophthalmic corticosteroid-antibiotic combination class)

  1. St. Jude Children's Research Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Maxitrol® — Competitive Intelligence Brief. https://druglandscape.com/ci/maxitrol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: